Beam Therapeutics Inc.

NasdaqGS BEAM

Beam Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 93.75%

Beam Therapeutics Inc. Gross Profit Margin is 93.75% for the Trailing 12 Months (TTM) ending September 30, 2024, a 42.65% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Beam Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 65.72%, a 762.14% change year over year.
Beam Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -9.93%, a 99.98% change year over year.
Beam Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -41,940.20%, a 88.54% change year over year.
Beam Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -365,983.33%, a -9.55% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: BEAM

Beam Therapeutics Inc.

CEO	Mr. John M. Evans M.B.A.
IPO Date	Feb. 6, 2020
Location	United States
Headquarters	238 Main Street
Employees	472
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years